PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsMore evidence for BRCA2 prostate cancer link

BioNews

More evidence for BRCA2 prostate cancer link

Published 9 June 2009 posted in News and appears in BioNews 412

Author

Ailsa Stevens

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

Results from an Icelandic study, published in the Journal of the National Cancer Institute, provide further evidence for the link between BRCA2 gene mutations and prostate cancer. Researchers from the Icelandic Cancer Registry in Reykjavik showed that one particular BRCA2 mutation, 999del5, was present in 1 in...

Results from an Icelandic study, published in the Journal of the National Cancer Institute, provide further evidence for the link between BRCA2 gene mutations and prostate cancer. Researchers from the Icelandic Cancer Registry in Reykjavik showed that one particular BRCA2 mutation, 999del5, was present in 1 in 20 of the prostate cancer patients studied and was linked to more aggressive forms of the disease.


While previous research at the Memorial Sloan-Kettering Cancer Centre in New York has shown that men in BRCA2 families are 3-5 times more likely to develop prostate cancer, this is the first time that researchers have taken a more in-depth look at the disease progression in such patients.


According to statistics published by Cancer Research UK, prostate cancer is the most common cancer in men in the UK, affecting 1 in 14, and accounts for nearly a quarter of male cancers. However, deaths from prostate cancer are relatively low since there a two 'grades' of prostate cancer: high-grade cancers may be lethal and will require active treatment through surgery and/or radiotherapy. However many cancers are 'low-grade' and, if small, may never cause any problems within a man's lifetime.


'The big challenge today is how to distinguish between a lethal cancer and a harmless one', said team leader Dr Laufey Tryggvadottir, speaking to New Scientist.


According to the researchers, the BRCA2 999del5 mutation is only carried by around 1 in 200 Icelandic men, with a similar incidence rate across Europe. So to obtain a sample of men liable to have prostate cancer associated with this mutation, Tryggvadottir and colleagues used the Icelandic Cancer Registry to pool prostate cancer patients with female relatives affected by breast cancer, giving a total of 596 men.


DNA analyses of stored tumour samples from these patients revealed that 30 men (5.7 per cent) carried the specific BRCA2 mutation. Furthermore, many of these men had unusually advanced disease at diagnosis and poor survival, dying an average of 10 years earlier than patients who didn't carry the mutation.


Given the probable rarity of the 999del5 mutation, the next stage will be 'to study whether these results can be confirmed for carriers of mutations at other locations within the BRCA2 gene', write the researchers. 'This finding suggests the need for prostate cancer surveillance of carriers of BRCA2 mutations', they conclude.


'In the short run, few men newly diagnosed with prostate cancer will gain much assurance from learning that they do not carry BRCA2 mutations', commented Sholom Wacholder of the National Cancer Institute in Bethesda, in an accompanying editorial. 'In the longer run, studies of the joint effects of treatment and genetic factors on prognosis and survival may allow for more tailored treatment decisions', he concludes.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
13 February 2013 • 2 minutes read

More genetic markers for prostate cancer found

by Stuart Scott

Three studies, published in the journal Nature Genetics, have uncovered ten genes that affect a man's risk of developing prostate cancer. The researchers hope that the discoveries will form the basis of a test that will predict men's chances of developing prostate cancer, as well as providing...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 June 2009 • 2 minutes read

BRCA2 mutation linked to rapid progression of prostate cancer

by Dr Rachael Panizzo

A study published in the British Journal of Cancer further confirms the association of the BRCA2 gene mutation with prostate cancer, linking the BRCA2 gene to a more rapid progression of the disease and more aggressive form of prostate cancer. The survival rate of men who are...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 June 2009 • 2 minutes read

Gene test for prostate cancer shows promise

by Stuart Scott

A cheap but powerful genetic test that can identify men with a high risk of developing prostate cancer - the commonest form of cancer in males - could soon be available according to US researchers. A study published in the New England Journal of Medicine suggests that the screening...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Draft UK Tissue and Embryos bill published

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

27 June 2022 • 2 minutes read

UK report reveals public attitudes to fertility, genomics and embryo research

27 June 2022 • 2 minutes read

Shortage of sperm donors despite men willing to donate

27 June 2022 • 2 minutes read

North East London CCG proposes offering three funded IVF cycles

27 June 2022 • 2 minutes read

Fibrosis drugs reverse ovarian ageing in mice

27 June 2022 • 2 minutes read

Gene implicated in motor neurone diseases discovered

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856